The estimated Net Worth of Karen Valentine is at least $655 millier dollars as of 19 January 2021. Ms. Valentine owns over 17,203 units of Constellation Pharmaceuticals Inc stock worth over $584,730 and over the last 16 years she sold CNST stock worth over $70,440. In addition, she makes $0 as Chief Legal Officer et General Counsel at Constellation Pharmaceuticals Inc.
Sign up
Ms. Valentine CNST stock SEC Form 4 insiders trading
Karen has made over 13 trades of the Constellation Pharmaceuticals Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently she exercised 17,203 units of CNST stock worth $197,835 on 19 January 2021.
The largest trade she's ever made was exercising 22,646 units of Constellation Pharmaceuticals Inc stock on 10 February 2020 worth over $260,429. On average, Karen trades about 1,520 units every 52 days since 2008. As of 19 January 2021 she still owns at least 17,203 units of Constellation Pharmaceuticals Inc stock.
You can see the complete history of Ms. Valentine stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Karen Valentine biography
Karen Higgins Valentine J.D. is the Chief Legal Officer and General Counsel of the Company. Prior to joining us, Ms. Valentine served as the chief legal officer and general counsel of Agenus Inc., a publicly traded immune-oncology company from September 2015 to July 2018 and served as vice president and general counsel of Agenus Inc. from January 2008 to September 2015. Prior to joining Agenus Inc. in 2004, Ms. Valentine was an associate in the biotechnology practice of Palmer & Dodge LLP (now Locke Lorde). Ms. Valentine is currently the president and a member of the board of directors of the Northeast Chapter of the Association of Corporate Counsel. Ms. Valentine holds a B.S. in neuroscience from Colgate University and received her J.D. from Boston University School of Law.
How old is Karen Valentine?
Karen Valentine is 48, she's been the Chief Legal Officer et General Counsel of Constellation Pharmaceuticals Inc since 2018. There are 8 older and 2 younger executives at Constellation Pharmaceuticals Inc. The oldest executive at Constellation Pharmaceuticals Inc is James Audia, 64, who is the Director.
What's Karen Valentine's mailing address?
Karen's mailing address filed with the SEC is C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE, MA, 02142.
Insiders trading at Constellation Pharmaceuticals Inc
Over the last 15 years, insiders at Constellation Pharmaceuticals Inc have traded over $36,293,867 worth of Constellation Pharmaceuticals Inc stock and bought 6,651,976 units worth $88,473,679 . The most active insiders traders include Peter Svennilson, Of The University Of Califo... et Anthony B Evnin. On average, Constellation Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $4,934,940. The most recent stock trade was executed by Mark A Goldsmith on 4 March 2021, trading 14,987 units of CNST stock currently worth $509,408.
What does Constellation Pharmaceuticals Inc do?
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
What does Constellation Pharmaceuticals Inc's logo look like?
Complete history of Ms. Valentine stock trades at Agenus Inc et Constellation Pharmaceuticals Inc
Constellation Pharmaceuticals Inc executives and stock owners
Constellation Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Jigar Raythatha,
President, Chief Executive Officer, Director -
Emma Reeve,
Chief Financial Officer, Senior Vice President, Treasurer -
Scott Braunstein,
Independent Director -
Mark Goldsmith,
Independent Chairman of the Board -
Robert Tepper,
Independent Director -
James Audia,
Director -
Elizabeth Trehu,
Independent Director -
Steven Hoerter,
Independent Director -
Ronald Aldridge,
IR Contact Officer -
Richard Levy,
Independent Director -
Jeffrey Humphrey,
Chief Medical Officer -
Karen Valentine,
Chief Legal Officer, General Counsel -
Patrick Trojer,
Chief Scientific Officer -
Group L Pcolumn Group Gp, L...,
-
Group L Pcolumn Group Iii, ...,
-
Group L Pgoeddel David V Sv...,
-
Group L Pcolumn Group Iii, ...,
-
Rock Ventures Lp Third Rock...,
-
Advisors Llc Orbi Med Globa...,
-
Of The University Of Califo...,
-
Capital, Llc Casdin Partner...,
-
Peter Svennilson,
Director -
Ventures Ii, Lp Spur Capita...,
-
Fund L.P.Topspin Biotech Fu...,
-
Berg Ltd Mountain,
10% owner -
Anthony B Evnin,
Director -
Group L Pcolumn Group Gp, L...,
-
Onco Ltd Precision,
10% owner -
Venture Investments, Llc Al...,
10% owner -
James E Deerfield Mgmt L.P....,
-
Jerry A Hatfield,
Sr. Vice President, Operations -
Michael John Hoffman,
President and CEO -
Daniel Ingram,
Senior V.P., Sales/Marketing -
James Ct Bolton,
Senior Vice President -
James A Lewis,
Director -
Frank J Mechura,
Director -
Angus Smith,
Director -
Donald P Deubel,
SVP, Corporate Technologies -
Christopher Phelan,
VP European Operations -
Walter Stanley Sobon,
Executive VP and CFO -
David J Waksman,
Senior Vice President -
Michael Dudley Mc Daniel,
Director -
John P Neafsey,
Director -
A Alexander Ii Taylor,
Director -
Group L Pcolumn Group Gp, L...,
-
Healthcare Capital Partners...,
-
Adrian Senderowicz,
Chief Medical Officer